Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Qualio. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Qualio or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Developing the undevelopable with Dave Miller, Chief Science Officer at AustinPx

44:02
 
Share
 

Manage episode 491919413 series 2833485
Content provided by Qualio. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Qualio or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

As complexity in pharmaceutical development reaches new heights — especially with over 60% of recent FDA novel molecular entities falling outside traditional drug design rules — the need for advanced formulation and manufacturing strategies has never been greater. Precision medicine is no longer a future goal; it’s a present necessity. And that’s exactly where AustinPx comes in.

At the forefront of this shift is AustinPx’s KinetiSol technology, a powerful platform designed to make the “undevelopable” developable — transforming poorly soluble, highly potent small molecules into scalable, patient-ready therapies.

Dr. Dave Miller, CSO, has spent more than 20 years in pharmaceutical R&D, helping drug developers navigate the challenges of bioavailability, permeability, and manufacturability for complex molecules.

Today, we’ll explore with Dave how CDMOs like AustinPx are empowering a new era of personalized treatment—while offering product protection strategies that help biopharma companies stand out in a competitive, cost-sensitive market.

Qualio website:
https://www.qualio.com/

Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast

Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8

Music by keldez

  continue reading

117 episodes

Artwork
iconShare
 
Manage episode 491919413 series 2833485
Content provided by Qualio. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Qualio or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

As complexity in pharmaceutical development reaches new heights — especially with over 60% of recent FDA novel molecular entities falling outside traditional drug design rules — the need for advanced formulation and manufacturing strategies has never been greater. Precision medicine is no longer a future goal; it’s a present necessity. And that’s exactly where AustinPx comes in.

At the forefront of this shift is AustinPx’s KinetiSol technology, a powerful platform designed to make the “undevelopable” developable — transforming poorly soluble, highly potent small molecules into scalable, patient-ready therapies.

Dr. Dave Miller, CSO, has spent more than 20 years in pharmaceutical R&D, helping drug developers navigate the challenges of bioavailability, permeability, and manufacturability for complex molecules.

Today, we’ll explore with Dave how CDMOs like AustinPx are empowering a new era of personalized treatment—while offering product protection strategies that help biopharma companies stand out in a competitive, cost-sensitive market.

Qualio website:
https://www.qualio.com/

Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast

Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8

Music by keldez

  continue reading

117 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play